Berberine looks promising for small intestinal bacterial overgrowth (SIBO), but the evidence is thinner than many gut health articles suggest. The best known study did not test berberine alone. It tested two herbal regimens, only one of which contained berberine, and found the herbs together cleared SIBO on a breath test about as often as the antibiotic rifaximin. A 2025 network meta-analysis ranked berberine first among 12 treatments, yet that ranking rests on a single 46 patient trial. That trial is an interim report from a larger head to head trial against rifaximin in China, whose full results are not yet published.
Evidence grade
Key takeaways
SIBO symptoms (bloating, gas, loose stools, abdominal discomfort) overlap with irritable bowel syndrome, celiac disease and other conditions. The American College of Gastroenterology's 2020 guideline recommends breath testing to diagnose it and covers antibiotics such as rifaximin as treatment. Self treating without a test risks missing something else, and gives you no way to tell whether a course worked.
If you have weight loss, blood in your stool, anemia, night sweats or symptoms that wake you up, see a doctor before trying any supplement.
What the Chedid study can and cannot tell you. It is the study most often quoted for "herbal SIBO protocols." Patients on herbs took one of two regimens. One (Candibactin-AR and BR) contained berberine sulfate, Indian barberry and coptis extracts alongside thyme and oregano oils. The other (Dysbiocide and FC Cidal) listed no berberine. Results were reported for both together, so the study cannot show what berberine itself added. In a smaller group of 14 people for whom rifaximin had failed, 8 (57%) cleared SIBO after a herbal course.
What the network meta-analysis adds. Zhang and colleagues pooled every randomized trial of SIBO treatments they could find. Berberine came out on top in the overall ranking and in people with SIBO and no other gut disease. But rankings in this kind of analysis can be driven by one small trial, and that is the case here. The authors themselves describe their findings as generating hypotheses that need direct comparison trials.
The IBS trial. Chen's trial did not test for SIBO, so it tells you about IBS symptoms rather than about clearing bacteria. Berberine at 200 mg twice a day reduced diarrhea, abdominal pain and urgency more than placebo over 8 weeks and was well tolerated.
The BRIEF-SIBO trial at Peking University Third Hospital (protocol published 2023) plans to randomize 180 patients to berberine 400 mg twice daily or rifaximin 400 mg twice daily for 2 weeks, with a negative breath test as the main outcome. It is the first trial designed specifically to show whether berberine alone is as good as rifaximin. An interim analysis of 46 patients, presented as a 2024 meeting abstract, is the berberine trial in Zhang's network meta-analysis. We will update this page when the full results are published.
The SIBO trials used a 2 week course.
As an Amazon Associate, Stacking Years earns from qualifying purchases. This does not affect our rankings.
Use only as directed on the current label
Thorne Berberine Dual Action combines berberine phytosome and berberine HCl; check the current label for serving details.
Best for: a berberine product from a brand that publishes its testing; check the label for berberine HCl content per capsule
View on Amazon ยท Affiliate link
The US National Center for Complementary and Integrative Health (NCCIH) describes berberine as considered safe at doses used in clinical studies, with nausea, diarrhea, bloating and constipation as the common side effects.
Rifaximin is the best studied option, with many more randomized trials behind it than berberine. Some people use lactoferrin for SIBO, though that evidence is earlier stage. For the wider picture of berberine's metabolic effects, see the berberine guide, and for how gut bacteria change with age, see the gut microbiome and aging.
This page is general information, not medical advice. Talk to your doctor before treating SIBO.
1. Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol. 2020;115(2):165-178. PMID 32023228
2. Chedid V, Dhalla S, Clarke JO, et al. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014;3(3):16-24. PMID 24891990
3. Zhang Q, Li H, Chen C, et al. Comparative efficacy of diverse therapeutic regimens for small intestinal bacterial overgrowth: a systematic network meta-analysis. Ther Adv Gastroenterol. 2025;18:17562848251399033. PMID 41394885
4. Guo H, Lu S, Zhang J, et al. Berberine and rifaximin effects on small intestinal bacterial overgrowth: study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO study). Front Pharmacol. 2023;14:1121435. PMID 36873985
5. Chen C, Tao C, Liu Z, et al. A randomized clinical trial of berberine hydrochloride in patients with diarrhea-predominant irritable bowel syndrome. Phytother Res. 2015;29(11):1822-1827. PMID 26400188
6. Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213-217. PMID 21870106
7. National Center for Complementary and Integrative Health. Diabetes and dietary supplements: what you need to know (berberine section). nccih.nih.gov